The primary endpoint of mean reduction in monthly migraine days (MMD) over the period 13-24 weeks in a total of 325 analyzed patients randomized across three arms showed a reduction of 8.5 days in ...

Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with ... announcement. The stock has rallied 20.8% ...

with the goal of informing healthcare providers and consumers about the advantages of non-oral migraine medications. How To ...